Home > Insider Trading > Filing (0001209191-23-019876)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	Biological Products, (No Disgnostic Substances) (2836)	814717861

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1827584	Seshadri Neervannan	C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-03-15	5,097	$0.00	56,934	No	4	M	Direct
Common Stock	Disposition	2023-03-16	357	$13.43	56,577	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-03-15	5,097	$0.00	5,097	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,291			No	4	M	Direct

Footnotes

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Company's common stock.
RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.